• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Cancer Lett. Author manuscript; available in PMC Sep 8, 2008.
Published in final edited form as:
PMCID: PMC1986742

Cellular responses to EGFR inhibitors and their relevance to cancer therapy


EGFR is a trans-membrane receptor tyrosine kinase that belongs to the HER family of receptors. The EGFR family plays an essential role in normal organ development by mediating morphogenesis and differentiation. Unlike normal cells that have tight regulatory mechanisms controlling EGFR pathways, tumor cells often have dysregulated EGFR signaling through receptor overexpression and/or mutation. This leads to proliferation under adverse conditions, invasion of surrounding tissues, and increased angiogenesis as well as resistance to radiation and chemotherapy. Therefore, EGFR is a legitimate therapeutic target. Numerous EGFR inhibitors are under development, but to date only four of them are FDA-approved, including two that inhibit the receptor's intracellular tyrosine kinase activity (gefitinib and erlotinib) and two that block extracellular ligand binding (cetuximab, and most recently panitumumab). In this review, we focus on how these different inhibitors affect EGFR signaling and the mechanisms by which they potentiate the effects of chemotherapy and radiation therapy. Numerous clinical trials have been conducted with these agents either as monotherapy, in combination with chemotherapy, or concurrently with radiation. Unfortunately, many of the clinical trials reported so far have shown at best limited gains; therefore, understanding the actions of these agents is essential to improving their efficacy in the treatment of cancers.

Keywords: EGFR inhibitor, epidermal growth factor receptor, radiosensitization, signaling, chemotherapy


Despite significant advances in systemic therapies, radiation oncology, and surgical techniques, many patients with cancer are still incurable. A novel therapeutic approach has been to target the epidermal growth factor receptor (EGFR), which is often mutated and/or overexpressed in many tumors and regulates proliferation, apoptosis, angiogenesis, tumor invasiveness, and distant metastases [1, 2]. Specifically, inhibition of the EGFR signaling pathways has been accomplished extracellularly with specific antibodies to block ligand binding or intracellularly with small molecule inhibitors. This review will focus on the cellular responses to these EGFR inhibitors and their implications for cancer therapy.


EGFR is a trans-membrane receptor tyrosine kinase that belongs to the HER family of receptors [3]. To date four member of this family have been identified including EGFR (HER1/erbB-1), HER2 (erbB-2/neu), HER3 (erbB-3) and HER4 (erbB-4). A wide variety of cancers express EGFR (Table 1). The N-terminus extracellular portion of EGFR can bind a variety of ligands. Based on their affinities for various receptors, these ligands are divided into three different groups. Epidermal growth factor (EGF), transforming growth factor β (TGF-β), and amphiregulin bind to EGFR; betacellulin, heparin-binding growth factors, and epiregulin can interact with both EGFR and ErbB4; and finally tomoregulins and heregulins bind to ErbB4 and occasionally to ErbB3 [4, 5]. HER2 has no known ligand, but it is the preferred heterodimerization partner for EGFR. Upon binding of ligand, multiple receptors, which normally exist as monomers, aggregate together at the cell surface to increase the probability of dimerization [6]. These molecules homodimerize with themselves or heterodimerize with other members of the family, bringing the intracellular C-terminal tyrosine kinase domains in close proximity to each other, resulting in autophosphorylation. Phosphorylation of these tyrosine residues allows docking of second messenger proteins that contain either Src homology 2 (SH2) or phosphotyrosine binding (PTB) domains to become activated [7], which then leads to activation of multiple downstream pathways.

The EGFR family plays an essential role in normal organ development by mediating morphogenesis and differentiation through effects on cell proliferation, differentiation, apoptosis, invasion, and angiogenesis [8, 9]. Unlike normal cells that have tight regulatory mechanisms controlling EGFR pathways, tumor cells often have dysregulated EGFR signaling, allowing them to proliferate under adverse conditions, invade surrounding tissues, and increase angiogenesis. Normally EGFR must be activated by a ligand to initiate downstream signaling, but tumor cells can circumvent this requirement through a number of mechanisms [10]. First, many cancers overexpress wildtype EGFR, which leads to ligand-independent EGFR activation. Secondly, cancers can also develop EGFR mutations, causing the receptor to be inappropriately activated. These mutations include point mutations or deletions in the tyrosine kinase activation domain, sometimes seen in non-small cell lung cancer (NSCLC) [11, 12], and deletion in the extracellular domain (EGFRvIII variant), seen frequently in glioblastomas [13-15]. Lastly, some cancers overexpress TGF-β, a ligand for EGFR, thereby establishing their own autocrine loop [16].

Numerous signaling pathways originate downstream of the EGFR [17] (see Figure 1). EGFR stimulation leads to Ras activation [18], which activates the extracellular signal pathway regulated kinase (ERK)/mitogen-activated protein kinase (MAP) kinase pathway. Activation of EGFR also leads to increased PI3 kinase activity, either directly or through Ras. PI3 kinase phosphorylates PIP2 to generate PIP3, which then recruits the serine/threonine kinases PDK1 and Akt to the inner cell membrane [19, 20]. Akt is then activated by being phosphorylated at both Ser 473 and Thr 308, the latter in response to PDK1. PTEN is a phosphatase that opposes the action of PI3 kinase, thereby reducing the level of phosphorylated (activated) Akt [21]. EGFR activation also results in phospholipase C gamma (PLC-γ) phosphorylation and subsequent hydrolysis of phosphatidylinositol 4,5 biphosphate (PIP2) into inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG), leading to protein kinase C (PKC) activation [22]. Other pathways activated by EGFR stimulation include the STAT3 pathway [23] and the p38 stress pathway.

Figure 1
Signaling pathways downstream of EGFR activation


Numerous strategies have been explored to target EGFR to inhibit tumor growth including monoclonal antibodies (MoAbs; e.g. cetuximab, panitumumab), small molecule tyrosine kinase inhibitors (TKIs; e.g. gefitinib, erlotinib), ligand-linked toxins, and antisense oligonucleotides. MoAbs block ligand from binding to the extracellular domain of the receptor whereas TKIs target the ATP-binding pocket of the cytoplasmic domain to inhibit receptor phosphorylation. To date, the FDA has approved only two MoAbs for clinical use, cetuximab and panitumumab and two TKIs, erlotinib and gefitinib.

In the early 1980s, a murine monoclonal antibody to the EGFR was demonstrated to inhibit the in vitro proliferation of Harvey sarcoma virus-transformed A431, a squamous cell carcinoma line that expresses up to 200-fold higher levels of EGFR than non-malignant cells [24, 25]. Because many pathologic specimens from epithelial malignancies demonstrated elevated EGFR, it was postulated that inhibition of EGFR-induced signaling might prove useful therapeutically. Initial in vivo experiments with xenografts of human tumors expressing EGFR in athymic mice demonstrated dose-dependent growth inhibition [26]. This antibody, known as C225, was humanized to create cetuximab (ErbituxR; ImClone System, Princeton, NJ). After the antibody binds to the EGFR, the receptor is internalized, then degraded, leading to receptor downregulation at the cell surface. The receptor is prevented from autophosphorylation and activation; therefore, downstream signaling is inhibited. However, studies by Mandic et al., have suggested that the antibody may transiently stimulate EGFR phosphorylation prior to downregulation [27].

A number of other anti-EGFR MoAbs are in development including EMD72000 (matuzumab) and hR3 (nimotuzumab), both of which are humanized mouse MoAbs like cetuximab. In contrast, panitumumab (VectoibixR; Abgenix, Fremont, CA) is a fully humanized antibody. It blocks ligand binding and causes receptor internalization, but not degradation [28]. Theoretically, such a fully humanized antibody should elicit fewer side effects. Cetuximab is FDA-approved for use in combination with irinotecan in the treatment of metastatic colorectal cancer, in combination with radiation for locally/regionally advanced SCCHN, and as monotherapy for recurrent/metastatic SCCHN after failing platinum-based chemotherapy. Panitumumab was recently approved by the FDA for the treatment of metastatic colorectal cancer refractory to standard chemotherapy agents.

Gefitinib (ZD1839, IressaR, Astra Zeneca, Wilmington, DE) is a reversible TKI that has been tested extensively in both pre-clinical models and in clinical trials. The drug has been shown to inhibit EGFR tyrosine kinase activity as low as the nanomolar range by competitively blocking the intracellular ATP-binding domain of the receptor [29, 30]. In contrast to cetuximab, gefitinib induces neither EGFR internalization nor degradation and thus does not decrease the level of EGFR protein.

In vitro and in vivo studies have demonstrated growth inhibition of multiple cell lines by gefitinib [31]. Studies using xenografts of human tumors derived from, ovarian, colon, lung, vulval, breast, and hormone-refractory prostate cancers showed that gefitinib potentiated the cytotoxic effects of many chemotherapeutic agents [32]. However, as will be discussed later, clinical trials have shown only modest efficacy of gefitinib as both a single agent and as part of a combination regimen in the treatment of patients with NSCLC. Hence, although the FDA had initially given wider approval to gefitinib for the treatment of NSCLC, because of these unimpressive results, it is now available only for patients who have failed both platinum-based and docetaxel chemotherapy and had previously benefited from gefitinib.

Erlotinib (OSI-774, Tarceva™, OSI Pharmaceuticals in collaboration with Genentech and Roche) potently and reversibly inhibits EGFR tyrosine kinase activity of both wild-type EGFR and the constitutively active mutant EGFRvIII at concentrations at nanomolar concentrations in vitro. Like gefitinib, erolotinib does not decrease the level of EGFR protein. Many clinical trials have been conducted to test the efficacy of erlotinib, some of which show positive results. Side effects of the erlotinib in these trials included skin rash and diarrhea [33]. Erlotinib is currently FDA-approved for the treatment of patients with locally advanced or metastatic NSCLC after failure of first-line chemotherapy and as first-line therapy for locally advanced, unresectable or metastatic pancreatic cancer in combination with gemcitabine.

TKIs with different specificities than gefitinib and erlotinib are under development. PKI-166 (Novartis International, Basel, Switzerland), GW572016 (GlaxoSmithKline, Research Triangle Park, NC), and ARRY-334543 (Array BioPharma, CO) inhibit both EGFR and ErbB-2-reversibly. In contrast, EKB-569 (Wyeth-Ayerst, Madison, NJ) is an irreversible dual inhibitor of these two receptors. High levels of HER2/neu can potentiate EGFR signaling making it difficult for EGFR inhibitors to block EGFR phosphorylation [34], hence scientific rationale exists for inhibiting both receptors. Only the results of clinical trials will tell whether these newer inhibitors have better efficacy than the older TKIs.


Mutations in genes encoding for EGFR or its signaling molecules are observed in many tumors. Glioblastomas often express a mutant variant of EGFR, known as EGFRvIII, which constitutively activates PI3K and confers enhanced tumorigenicity [14]. Mellinghoff et al. studied patients with glioblastomas who had been treated with EGFR kinase inhibitors [35]. Their study demonstrated that patients with co-expression of EGFRvIII and PTEN were more likely to show a radiologic response to an EGFR inhibitor. Furthermore, glioblastoma cells co-expressing these two molecules were sensitive to erlotinib. A possible explanation is that loss of PTEN might activate the Akt pathway independently of EGFR and render it insensitive to EGFR inhibition. These results suggest that identification of patient populations with certain mutations may lead to specifically directed therapies.

EGFR is overexpressed in 80% of NSCL and mutated in a smaller percentage. Pao et al. found that 81% of patients with Stages I-IIIA NSCLC who responded to gefitinib or erlotinib had mutations either in or around exon 19 [36]. Paez, et al. analyzed NSCLC specimens from patients who did and did not respond to gefitinib. Tumors from patients whose disease progressed on gefitinib showed no mutations in exons 18 to 24. In contrast, specimens from gefitinib-responsive tumors contained mutations within the ATP-binding pocket located in the EGFR-kinase activation domain [12]. Likewise, Lynch et al. showed that 8 of 9 patients who responded to gefitinib had a mutation of EGFR in the kinase activation domain whereas all seven patients who failed to respond to gefitinib had wildtype EGFR [11]. These last two studies both examined the effect these EGFR mutations in cell lines. Cell lines with mutant EGFR showed enhanced tyrosine kinase activity in response to EGF, and a minimal concentration of gefitinib was able to completely inhibit EGFR autophosphorylation in these cells. In contrast, cell lines with wildtype EGFR required concentrations 100-fold higher to achieve the same level of inhibition. These three studies showed that certain groups of patients were more likely to have EGFR mutations in the kinase activation domain and consequently more likely to respond to gefitinib: women, patients with adenocarcinoma or bronchoalveolar cell carcinoma, non-smokers, and Asians.

These mutations in the kinase activation domain of EGFR activate the receptor. Tumors that contain these mutated receptors are felt to be “addicted” to them in the sense that their survival is absolutely dependent on this activation [37]. Hence if the pathway is disrupted through the use of inhibitors, these cell readily die. This term of oncogene addiction was first described in characterizing the response of chronic myelogenous leukemia to Gleevac monothearpy [37, 38].


EGFR inhibition has significant effects on cellular proliferation. Huang et al. showed that micromolar concentrations of gefitinib inhibited cell proliferation in a dose-dependent manner in SCCHN cell lines [39]. Even cell lines with relatively low levels of EGFR expression showed modest levels of inhibition. Flow cytometric analysis demonstrated that gefitinib treatment led to an accumulation of cells in the G1 phase with a simultaneous decrease in cell numbers in S phase. This G1 phase arrest induced by EGFR inhibition is thought to be due to an increase in the levels of the cyclin-dependent kinase inhibitor p27 [40].


EGFR activation results in PLC-γ phosphorylation and subsequent hydrolysis of phosphatidylinositol 4,5 biphosphate (PIP2) into inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG) (see Figure 1). This in turns leads to the release of gelsolin and other actin-binding proteins that can modify the actin cytoskeleton [41, 42]. Hydrolysis of PIP2 occurs preferentially at the leading edge of a cell, which provides asymmetry in intracellular signaling and leads to the formation of lamellopodia during EGFR-mediated migration. Inhibition of PLC-γ blocks glioma cell motility and invasion into fetal rat brain aggregates [43] as well as EGFR-mediated migration of breast carcinoma cells [44].

The PI3K pathway, which is also downstream of EGFR activation, is involved in migration as well [45] through PIP3 accumulation, which leads to the activation of Rho family GTPases including Rac and/or cdc42 [46]. Activated Rac recruits a protein complex that leads to cycles of activation and inactivation of gelsolin. This leads to severing and dissolution of actin filament networks and creation of sites of actin reassembly. PIP3 may also enhance PLC-γ-catalyzed hydrolysis [47] and provide a mechanism by which the two pathways may cooperate to increase cell motility. Also, evidence suggests that PI3K can influence EGF-mediated motility by regulating translocation of PLC-γ to the leading edge of a migrating cell [44].

Other pathways that may also be involved in EGFR-mediated migration and invasion include the MAP kinase and protein kinase C delta (PKC-δ) pathways [48, 49]. PKC-δ was shown to be overexpressed in two invasive prostate cell lines relative to normal prostate epithelial cells [50]. Furthermore, inhibition of PKC-δ with a chemical inhibitor and specific siRNA were able to decrease invasion and migration of both cell lines. Whether these downstream pathways are also directly affected by EGFR inhibition remains to be determined.


Decreased expression of vascular endothelial growth factor (VEGF), a key angiogenic factor, may account for some of the inhibition of tumor growth by EGFR blockade in vivo. EGF induces VEGF expression in many cell lines [51, 52]. Conversely, our own data and that of many other groups indicate that pharmacological inhibition of EGFR can decrease VEGF expression and consequently angiogenesis in many tumor types [31, 39, 53-58]. Particularly interesting is a study that showed that the development of resistance to anti-EGFR antibody therapy in human tumor xenografts correlated with VEGF overexpression [59]. Furthermore, this acquired lack of responsiveness to the anti-EGFR therapy could be mimicked by VEGF overexpression engineered by gene transfection.

C225 has been demonstrated to enhance the inhibitory effects of antisense VEGF in tumor xenografts of human GEO colon cancer cells in immunodeficient mice [54]. Mice treated with the combination of C225 and antisense VEGF demonstrated improved survival and local tumor control than with either agent alone. Based on this and other preclinical studies, clinical trials are now being conducted using erlotinib in combination with the anti-VEGF antibody bevacizumab (Avastin, Genentech, San Francisco, CA) in advanced NSCLC [60]. The combination of bevacizumab, conventional chemotherapy, and an anti-EGFR antibody (panitumumab or cetuximab) is being evaluated in metastatic colorectal carcinoma [61]. Furthermore, agents that are dual EGFR/VEGF inhibitors, such as ZD6474 (Astra-Zeneca, Wilmington, DE) have been studied pre-clinically [62] and are now in clinical trials.


Growth factors have been shown to mediate cellular responses to radiation in numerous tissues. Some studies have shown that EGF treatment leads to radiosensitization [63-65]. However, in retrospect, it is very possible that radiosensitization with EGF in these studies occurred because prolonged exposure to EGF resulted in degradation of EGFR. In fact, most studies have shown the opposite, that activating the EGFR pathway leads to decreased sensitivity to radiation. For example, treatment of MCF-7 breast cancer cells with EGF prior to irradiation led to increased radioresistance, which was inhibited by antibodies to EGFR [66]. Furthermore, cell lines derived from head and neck tumors and xenografts that overexpress EGFR have been observed to be radioresistant [67, 68]. Akimoto et al. found an inverse correlation between EGFR expression and the radiocurability of murine carcinomas [69]. Transfection of the mutant EGFRvIII receptor into astrocytes led to radioresistance [70].

Numerous studies have examined the effect of EGFR inhibition on the radiation response. Harari and colleagues found that the EGFR MoAb C225 enhanced the radiosensitivity of HNSCC as measured by clonogenic survival [71]. C225 also augments radiation killing in vivo in HNSCC xenografts implanted in nude mice [55]. The same group showed that the small molecule inhibitors gefitinib and erlotinib also increased both in vitro and in vivo radiosensitivity [39, 72]. Other groups have confirmed that C225 or gefitinib leads to enhanced killing in response to radiation in vitro and in vivo using diverse cell types including HNSCC, colon, ovarian, NSCLC, and breast cancer lines [73-76].

How EGFR inhibitors increase sensitivity to radiation is not completely understood. The C225 antibody causes an increase in the proportion of cells in G1, which is a more radiosensitive phase, and a concomitant decrease in the proportion in the S phase, which is more radioresistant [71]. Gefitinib [77] and erlotinib [72] also cause this cell cycle redistribution, which could contribute to radiosensitivity. Another potential mechanism of radiosensitization is via increased apoptosis. Huang et al. showed that the C225 antibody increased radiation-induced apoptosis at the same time that it increased expression of Bax, a pro-apoptotic protein, and decreased expression of Bcl-2, an anti-apoptotic protein [71]. Likewise, gefitinib has also been found to increase radiation-induced apoptosis [39, 76]. However, in epithelial cells, apoptosis may constitute a relatively small component of cell deaths induced by radiation [78]

There are data suggesting that EGFR inhibition can decrease DNA repair following radiation. Based on their experimental data, Dittmann, et al. have proposed that ionizing radiation triggers EGFR import into the nucleus [79]. According to their model, EGFR interacts with DNA-PK, a protein involved in DNA damage repair, thus leading to increased nuclear activity of DNA-PK. The same group also showed that EGFR blockade with the C225 antibody abolished EGFR import into the nucleus and radiation-induced activation of DNA-PK, thus inhibiting DNA repair and increasing the radiosensitivity of treated cells [80]. Consistent with this model, Huang and Harari [39] showed that C225 decreased the repair of sublethal damage following radiation and caused redistribution of DNA-PK from the nucleus to the cytosol. This shift in DNA-PK from the nucleus to the cytosol has been documented by other groups in response to either anti-EGFR monoclonal antibodies or gefitinib [81].

Treatment interruptions are associated with worse local control for certain cancers, particularly SCCHN [82]. One explanation for this is that after many doses of radiation, cells that are not killed may actually be induced to proliferate faster. It has been hypothesized that the mechanism underlying this phenomenon termed “accelerated repopulation” may be the activation of EGFR signaling by radiation. In fact, irradiation of cells in vitro and tumors in vivo has been shown to lead to EGFR phosphorylation and activation of downstream signaling pathways [69, 83-85]. However, it is not clear whether this actually occurs in patients undergoing irradiation. Eriksen, et al. found some support for this hypothesis in their study showing that patients with SCCHN achieved better local control with an accelerated radiotherapy schedule, but only if their tumors overexpressed EGFR [86]. If ongoing studies continue to provide further evidence that EGFR overactivity may be responsible for the phenomenon of accelerated repopulation, then inhibition of downstream kinase activity may potentially be an alternative to accelerated radiotherapy for overcoming repopulation.

In addition to the mechanisms discussed above that are apparent in vitro (increased apoptosis, cell cycle redistribution, decreased DNA repair and inhibition of accelerated repopulation), there may be additional factors that are only important in vivo. As discussed previously, EGFR inhibition has effects on VEGF/angiogenesis and migration/invasion that could increase in vivo radiosensitivity. Radiation itself can upregulate the expression of VEGF, and there are reports in the literature that suggest that decreasing VEGF expression following radiation can augment tumor control in vivo [87-89].


EGF treatment of cells has been shown to be associated with resistance to chemotherapeutic agents including doxorubicin and topoisomerase II inhibitors [90, 91]. Fan, et al. found significant tumor regression of A431 squamous cell carcinoma xenografts in nude mice treated with C225 in combination with cisplatin whereas either agent by itself had no effect [92]. Likewise, studies with doxorubicin in combination with anti-EGFR monoclonal antibodies demonstrated marked tumor regression of A431 and MDA-468 xenografts in athymic mice, but only temporary growth inhibition when either agent was used by itself [93]. Chemosensitization has also been demonstrated with small molecule EGFR inhibitors. Sirotnak, et al. reported that the combination of gefitinib with platinum-containing chemotherapy resulted in several-fold higher growth inhibition in human tumor cell explants in mice compared to chemotherapy alone [32]. Gefitinib potentiated growth inhibition by chemotherapy irrespective of EGFR expression levels.

The effect of EGFR inhibition on chemosensitization may be related to suppression of DNA damage repair. Friedmann, et al. found that the addition of gefitinib delayed repair of DNA strand breaks after etoposide treatment and delayed repair of DNA interstrand cross-links after cisplatin treatment [94]. Gefitinib was also found to inhibit the removal of oxaliplatin DNA adducts [95].

Similar to ionizing radiation, chemotherapeutic agents such as cisplatin, [96] oxaliplatin, 5-FU [97] and paclitaxel [98] can lead to increased EGFR phosphorylation and activation. EGFR inhibitors could increase chemotherapy-induced killing by interfering with this response. Consistent with this idea, the ability of gefitinib to cooperate in cell killing by oxaliplatin or 5-FU correlated with the ability of these two chemotherapeutic agents to induce EGFR phosphorylation [97].

In the “Radiosensitization” section, it was mentioned that the accumulation of cells in the G1 phase by EGFR inhibitors could potentially explain their radiosensitization since cells are more radiosensitive in this phase of the cell cycle. However, this cell cycle redistribution could have an adverse effect in terms of response to chemotherapy. Chun, et al. found that gefitinib followed by gemcitabline was less toxic compared with the reverse combination [99]. This was hypothesized to be partly due to the fact that the former sequence led to an accumulation of cells in the G1 phase prior to exposure to gemcitabine, which has greater toxicity for cells in S phase. Similar sequence-dependent differences in cytotoxicty have been demonstrated for oxaliplatin [95] and a topoisomerase inhibitor [100] although these agents are not S-phase specific in their killing. Therefore, the precise sequencing of EGFR inhibitors in regard to chemotherapeutic agents could be an important factor in their efficacy in clinical trials.


The addition of cetuximab to radiotherapy in SCCHN has led to improved overall survival and locoregional control in a clinical phase III trial. Bonner, et al., randomized 424 patients with locally advanced SCCHN to radiotherapy plus weekly cetuximab or radiotherapy alone [101]. After a median follow-up of 54 months, overall survival was 55% months at three years in the combined therapy arm versus 45% in the radiation alone arm (median 49 months vs. 29 months), a difference that reached statistical significance (p=0.03). Local control was also significantly improved in the radiation plus cetuximab arm at 50% versus 41% in the radiation alone arm (median 24 months versus 15 months). Cetuximab was associated with the development of acneiform rash in a majority of patients and hypersensitivity reactions in four patients. A major critique of this study is that none of the patients received chemotherapy, which is routinely used today in combination with radiation in patients with SCCHN. However, it is proof of principle that EGFR inhibition can improve the efficacy of radiotherapy in patients. There is currently a randomized trial underway (RTOG 0522) in which patients are randomized to radiation and cisplatin versus the same regimen plus cetuximab.


I. Gefitinib and non-small cell lung cancer

While some tumors clearly exhibit dramatic shrinkage in response to EGFR inhibitors [11, 12], clinical phase III randomized trials have not shown a survival advantage with gefitinib. In the phase III ISEL trial for locally advanced or metastatic NSCLC, gefitinib monotherapy failed to demonstrate a survival benefit in patients who had received one or two prior chemotherapy regimens [102]. Likewise, in the SWOG0023 trial for patients with Stage III NSCLC, gefitinib monotherapy did not improve survival after completion of induction and consolidation chemo-radiotherapy [103]. In the Iressa Dose Evaluation in Advanced Lung Cancer (IDEAL) trial gefitinib did not show single-agent activity in patients with NSCLC [104, 105]. Furthermore, gefitinib did not enhance the activity of standard chemotherapy in patients with advanced NSCLC in the Iressa NSCLC Trial Assessing Combination Treatment (INTACT) studies [106-108]. Because of the disappointing results in these trials, the use of gefitinib is currently restricted by the FDA to patients who had previously shown benefit from the drug.

II. Erlotinib and non-small cell lung cancer

In contrast to the studies with gefitinib, one large phase III randomized trial, the National Cancer Institute of Canada BR.21 study, has confirmed a survival benefit to erlotinib in NSCLC [109]. Patients with stage IIIB or IV disease who had failed one or two prior chemotherapy regimens were randomized to erlotinib or placebo. Progression-free survival in the two groups was 2.2 months and 1.8 months, respectively (P < 0.001), and overall survival was 6.7 months and 4.7 months, respectively (P < 0.001).

However, two other large clinical trials have failed to show a benefit to erlotinib in combination with standard chemotherapy. In the TALENT trial, patients with untreated advanced NSCLC were randomized to receive either erlotinib or placebo along with gemcitabine/cisplatin [110]. No statistically significant difference in overall survival or time to progression was observed between the two groups. In the TRIBUTE trial, patients with untreated stage IIIB or IV NSCLC were randomly assigned to erlotinib or placebo combined with up to 6 cycles of carboplatin and paclitaxel, followed by maintenance monotherapy. No difference was observed in objective response, time to progression, or overall survival. However, patients without a history of smoking demonstrated improved survival with erolitnib [111].

III. EGFR inhibitors and cancers of the gastrointestinal tract

Cetuximab was found to have clinically significant activity when given alone or in combination with irinotecan in patients with irinotecan-refractory colorectal cancer [112]. An international multi-center phase III trial compared panitumumab as a single agent to best supportive care in patients with metastatic colorectal cancer who had failed conventional chemotherapy. The results showed that the panitumumab arm significantly improved the progression-free survival over the control arm but did not affect overall survival [113]. A phase III trial in patients with advanced pancreatic carcinoma showed that the addition of erlotinib to gemcitabine improved overall survival and progression-free survival compared with gemcitabine alone [114].

In many of these trials, it has been observed that patients who develop the characteristic acneiform rash with treatment of EGFR inhibitors tended to have a higher response rates than those who did not develop a rash. In the phase III panitumumab trial for metastatic colorectal cancer, rash was reported in 90% of patients, and increased severity significantly correlated with improved median overall survival [113].


There is a wealth of preclinical data indicating why EGFR inhibitors should be effective in controlling cancers. These agents could block cancer growth via inhibition of tumor proliferation, apoptosis, angiogenesis, migration, invasion, and metastases. However, clinical trials in patients with cancer have shown only modest gains with these inhibitors, particularly when they have been given as monotherapy. There appears to be greater promise when these agents are combined with radiation or chemotherapy. A variety of mechanism may explain the potentiation of conventional cytotoxic therapy with EGFR inhibitors, including the suppression of DNA damage repair. A more thorough understanding of these mechanisms is required in order to maximize the benefit from EGFR inhibitors in the treatment of cancer.


The preparation of this manuscript was in part supported by NIH R01 CA093638.


non-small cell lung cancer
squamous cell carcinoma of the head and neck
monoclonal antibody


Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.


1. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist. 2002;7(Suppl 4):2–8. [PubMed]
2. Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther. 2004;102:37–46. [PubMed]
3. Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37(Suppl 4):S3–8. [PubMed]
4. Riese DJ, Kim ED, Elenius K, Buckley S, Klagsbrun M, Plowman GD, et al. The epidermal growth factor receptor couples transforming growth factor-alpha, heparin-binding epidermal growth factor-like factor, and amphiregulin to neu, ErbB-3, and ErbB-4. J Biol Chem. 1996;271:20047–20052. [PubMed]
5. Riese DJ, II, Komurasaki T, Plowman GD, Stern DF. Activation of ErbB4 by the bifunctional epidermal growth factor family hormone epiregulin is regulated by ErbB2. J Biol Chem. 1998;273:11288–11294. [PubMed]
6. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol/Hematol. 1995;19:183–232. [PubMed]
7. Pawson T. Protein modules and signalling networks. Nature. 1995;373:573–580. [PubMed]
8. Partanen A. Epidermal growth factor and transforming growth factor-alpha in the development of epithelial-mesenchymal organs of the mouse. Curr Top Dev Biol. 1990;24:31–55. [PubMed]
9. Adamson E. Developmental activities of the epidermal growth factor receptor. Curr Top Dev Biol. 1990:1–29. [PubMed]
10. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366:2–16. [PubMed]
11. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–2139. [PubMed]
12. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–1500. [PubMed]
13. Ekstrand A, Longo N, Hamid M, Olson J, Liu L, Collins V, et al. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene. 1994;8:2313–2320. [PubMed]
14. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci. 1994;91:7727–7731. [PMC free article] [PubMed]
15. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci. 1992;89:2965–2969. [PMC free article] [PubMed]
16. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;53:3579–3584. [PubMed]
17. Carpenter G. The EGF receptor: A nexus for trafficking and signaling. Bioessays. 2000;22:697–707. [PubMed]
18. Maruta H, Burgess AW. Regulation of the Ras signalling network. Bioessays. 1994;16:489–496. [PubMed]
19. Luo J, Manning B, Cantley L. Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer Cell. 2003;4:257–262. [PubMed]
20. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase Akt pathway in human cancer. Nat Rev Cancer. 2002;2:489–501. [PubMed]
21. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/akt pathway. Proc Natl Acad Sci. 1999;96:4240–4245. [PMC free article] [PubMed]
22. Falasca M, Logan SK, Lehto VP, Baccante G, Lemmon MA, Schlessinger J. Activation of phospholipase C gamma by PI 3-kinase-induced PH domain-mediated membrane targeting. EMBO J. 1998;17:414–422. [PMC free article] [PubMed]
23. Turkson J, Jove R. STAT proteins: Novel molecular targets for cancer drug discovery. Oncogene. 2000;19:6613–6626. [PubMed]
24. Kawamoto T, Mendelsohn J, Le A, Sato GH, Lazar CS, Gill GN. Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells. J Biol Chem. 1984;259:7761–7766. [PubMed]
25. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med. 1983;1:511–529. [PubMed]
26. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1984;44:1002–1007. [PubMed]
27. Mandic R, Rodgarkia-Dara C, Zhu L, Folz B, Bette M, Weihe E, et al. Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor. FEBS Letters. 2006;580:4793–4800. [PubMed]
28. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 2001;38:17–23. [PubMed]
29. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, et al. ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002;62:5749–5754. [PubMed]
30. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther. 1999;82:241–250. [PubMed]
31. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res. 2001;7:1459–1465. [PubMed]
32. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. 2000;6:4885–4892. [PubMed]
33. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncology. 2001:3267–3279. [PubMed]
34. Christensen JG, Schreck RE, Chan E, Wang X, Yang C, Liu L, et al. High levels of Her-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin Cancer Res. 2001;7:4230–4238. [PubMed]
35. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353:2012–2024. [PubMed]
36. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from “Never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci. 2004;101:13306–13311. [PMC free article] [PubMed]
37. Weinstein I. Addiction to oncogenes -- the Achilles heal of cancer. Science. 2002;297:63–64. [PubMed]
38. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353:172–187. [PubMed]
39. Huang SM, Li J, Armstrong EA, Harari PM. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa) Cancer Res. 2002;62:4300–4306. [PubMed]
40. Wu X, Rubin M, Fan Z, DeBlasio T, Soos T, Koff A, et al. Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene. 1996;12:1397–1403. [PubMed]
41. Chen P, Murphy-Ullrich JE, Wells A. A role for gelsolin in actuating epidermal growth factor receptor-mediated cell motility. J Cell Biol. 1996;134:689–698. [PMC free article] [PubMed]
42. Chen P, Xie H, Sekar MC, Gupta K, Wells A. Epidermal growth factor receptor-mediated cell motility: Phospholipase C activity is required, but mitogen-activated protein kinase activity is not sufficient for induced cell movement. J Cell Biol. 1994;127:847–857. [PMC free article] [PubMed]
43. Khoshyomn S, Penar PL, Rossi J, Wells A, Abramson DL, Bhushan A. Inhibition of phospholipase C-gamma1 activation blocks glioma cell motility and invasion of fetal rat brain aggregates. Neurosurgery. 1999;44:568–577. discussion 577-568. [PubMed]
44. Piccolo E, Innominato PF, Mariggio MA, Maffucci T, Iacobelli S, Falasca M. The mechanism involved in the regulation of phospholipase C-gamma1 activity in cell migration. Oncogene. 2002;21:6520–6529. [PubMed]
45. Pukac L, Huangpu J, Karnovsky MJ. Platelet-derived growth factor-BB, insulin-like growth factor-I, and phorbol ester activate different signaling pathways for stimulation of vascular smooth muscle cell migration. Exp Cell Res. 1998;242:548–560. [PubMed]
46. Azuma T, Witke W, Stossel TP, Hartwig JH, Kwiatkowski DJ. Gelsolin is a downstream effector of rac for fibroblast motility. Embo J. 1998;17:1362–1370. [PMC free article] [PubMed]
47. Scharenberg AM, Kinet JP. Ptdins-3,4,5-p3: A regulatory nexus between tyrosine kinases and sustained calcium signals. Cell. 1998;94:5–8. [PubMed]
48. Alonso-Escolano D, Medina C, Cieslik K, Radomski A, Jurasz P, Santos-Martinez MJ, et al. Protein kinase C delta mediates platelet-induced breast cancer cell invasion. J Pharm and Exp Ther. 2006;318:373–380. [PubMed]
49. Kruger JS, Reddy KB. Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells. Molecular Cancer Research. 2003;1:801–809. [PubMed]
50. Kharait S, Dhir R, Lauffenburger D, Wells A. Protein kinase C delta signaling downstream of the EGF receptor mediates migration and invasiveness of prostate cancer cells. Biochem Biophys Res Commun. 2006;343:848–856. [PubMed]
51. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiology. Mol Biol Cell. 1993;4:121–133. [PMC free article] [PubMed]
52. Maity A, Pore N, Lee J, Solomon D, O'Rourke DM. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3'-kinase and distinct from that induced by hypoxia. Cancer Res. 2000;60:5879–5886. [PubMed]
53. Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res. 2000;6:1936–1948. [PubMed]
54. Ciardiello F, Bianco R, Damiano V, Fontanini G, Caputo R, Pomatico G, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res. 2000;6:3739–3747. [PubMed]
55. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res. 2000;6:2166–2174. [PubMed]
56. Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res. 1999;5:257–265. [PubMed]
57. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol. 1997;151:1523–1530. [PMC free article] [PubMed]
58. Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD, Maity A. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res. 2006;66:3197–3204. [PubMed]
59. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res. 2001;61:5090–5101. [PubMed]
60. Sandler A, Herbst R. Combining targeted agents: Blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin Cancer Res. 2006;12:4421–4425. [PubMed]
61. Wainberg Z, Hecht JR. Panitumumab in colon cancer: A review and summary of ongoing trials. Expert Opinion on Biological Therapy. 2006;6:1229–1235. [PubMed]
62. Ryan AJ, Wedge SR. ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer. 2005;92(Suppl 1):S6–13. [PMC free article] [PubMed]
63. Kwok TT, Sutherland RM. Enhancement of sensitivity of human squamous carcinoma cells to radiation by epidermal growth factor. J Natl Cancer Inst (Bethesda) 1989;81:1020–1024. [PubMed]
64. Kwok TT, Sutherland RM. Differences in EGF related radiosensitisation of human squamous carcinoma cells with high and low numbers of EGF receptors. Br J Cancer. 1991;64:251–254. [PMC free article] [PubMed]
65. Bonner JA, Maihle NJ, Folven BR, Christianson TJ, Spain K. The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. Int J Radiat Oncol Biol Phys. 1994;29(2):15243–15247. [PubMed]
66. Wollman R, Yahalom J, Maxy R, Pinto J, Fuks Z. Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cells in vitro. Int J Radiat Oncol Biol Phys. 1994;30:91–98. [PubMed]
67. Miyaguchi M, Takeuchi T, Morimoto K, Kubo T. Correlation of epidermal growth factor receptor and radiosensitivity in human maxillary carcinoma cell lines. Acta Otolaryngol. 1998;118:428–431. [PubMed]
68. Sheridan MT, O'Dwyer T, Seymour CB, Mothersill CE. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Investig. 1997;5:180–186. [PubMed]
69. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK, Milas L. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res. 1999;5:2884–2890. [PubMed]
70. Li B, Yuan M, Kim I, Chang C, Bernhard E, Shu H. Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/Akt pathway and promotes radioresistance in cells of astrocytic origin. Oncogene. 2004;23:4594–4602. [PubMed]
71. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999;59:1935–1940. [PubMed]
72. Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva) Cancer Res. 2005;65:3328–3335. [PubMed]
73. Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Caputo R, et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa) Clin Cancer Res. 2002;8:3250–3258. [PubMed]
74. Bonner JA, Raisch KP, Trummell HQ, Robert F, Meredith RF, Spencer SA, et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol. 2000;18:47S–53S. [PubMed]
75. Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res. 2000;6:701–708. [PubMed]
76. Solomon B, Hagekyriakou J, Trivett MK, Stacker SA, McArthur GA, Cullinane C. EGFR blockade with ZD1839 (“Iressa”) potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2003;55:713–723. [PubMed]
77. Huang XL, Pawliczak R, Cowan MJ, Gladwin MT, Madara P, Logun C, et al. Epidermal growth factor induces p11 gene and protein expression and down-regulates calcium ionophore-induced arachidonic acid release in human epithelial cells. J Biol Chem. 2002;277:38431–38440. [PubMed]
78. Brown JM, Wilson G. Apoptosis genes and resistance to cancer therapy: What does the experimental and clinical data tell us? A review. Cancer Biol Ther. 2003:477–490. [PubMed]
79. Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L, et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem. 2005;280:31182–31189. [PubMed]
80. Dittmann K, Mayer C, Rodemann HP. Inhibition of radiation-induced EGFR nuclear import by C225 (cetuximab) suppresses DNA-pk activity. Radiother Oncol. 2005:157–161. [PubMed]
81. Friedmann BJ, Caplin M, Savic B, Shah T, Lord CJ, Ashworth A, et al. Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. Mol Cancer Ther. 2006;5(2):209–218. [PubMed]
82. Tarnawski R, Fowler J, Skladowski K, Swierniak A, Suwinski R, Maciejewski B, et al. How fast is repopulation of tumor cells during the treatment gap? Int J Radiat Oncol Biol Phys. 2002;54(1):229–236. [PubMed]
83. Contessa JN, Hampton J, Lammering G, Mikkelsen RB, Dent P, Valerie K, et al. Ionizing radiation activates Erb-B receptor dependent Akt and p70 s6 kinase signaling in carcinoma cells. Oncogene. 2002:4032–4041. [PubMed]
84. Dent P, Reardon DB, Park JS, Bowers G, Logsdon C, Valerie K, Schmidt-Ullrich R. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell. 1999;10:2493–2506. [PMC free article] [PubMed]
85. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, Todd DG, Valerie K, Kavanagh BD, et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene. 1997;15:1191–1197. [PubMed]
86. Eriksen JG, Steiniche T, Askaa J, Alsner J, Overgaard J. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys. 2004;58:561–566. [PubMed]
87. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999:3374–3378. [PubMed]
88. Hess C, Vuong V, Hegyi I, Riesterer O, Wood J, Fabbro D, Glanzmann C, Bodis S, Pruschy M. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer. 2001:2010–2016. [PMC free article] [PubMed]
89. Zips D, Eicheler W, Geyer P, Hessel F, Dorfler A, Thames HD, Haberey M, Baumann M. Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition. Cancer Res. 2005:5374–5379. [PubMed]
90. Tsang WP, Kong SK, Kwok TT. Epidermal growth factor induction of resistance to topoisomerase II toxins in human squamous carcinoma A431 cells. Oncol Rep. 2006;16(4):789–793. [PubMed]
91. Kwok TT, Sutherland RM. Epidermal growth factor reduces resistance to doxorubicin. Int J Cancer. 1991;49(1):73–76. [PubMed]
92. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established a431 cell xenografts. Cancer Res. 1993;53:4637–4642. [PubMed]
93. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH, Jr., et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst. 1993;85:1327–1333. [PubMed]
94. Friedmann B, Caplin M, Hartley JA, Hochhauser D. Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839) Clin Cancer Res. 2004;10(19):6476–6486. [PubMed]
95. Xu JM, Azzariti A, Severino M, Lu B, Colucci G, Paradiso A. Characterization of sequence-dependent synergy between ZD1839 (‘Iressa’) and oxaliplatin. Biochem Pharmacol. 2003;66:551–563. [PubMed]
96. Benhar M, Engelberg D, Levitzki A. Cisplatin-induced activation of the EGF receptor. Oncogene. 2002;21:8723–8731. [PubMed]
97. Van Schaeybroeck S, Karaiskou-McCaul A, Kelly D, Longley D, Galligan L, Van Cutsem E, Johnston P. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res. 2005;11(20):7480–7489. [PubMed]
98. Sumitomo M, Asano T, Asakuma J, Asano T, Horiguchi A, Hayakawa M. ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway. Clin Cancer Res. 2004;10:794–801. [PubMed]
99. Chun PY, Feng FY, Scheurer AM, Davis MA, Lawrence TS, Nyati MK. Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Research. 2006;66:981–988. [PubMed]
100. Azzariti A, Xu JM, Porcelli L, Paradiso A. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839) Biochem Pharmacol. 2004:135–144. [PubMed]
101. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578. [PubMed]
102. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa survival evaluation in lung cancer) Lancet. 2005;366:1527–1537. [PubMed]
103. Kelly K, Gaspar LE, Chansky K, Albain KS, Crowley J, Gandara DR. Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non-small cell lung cancer. Proc Am Assoc Clin Oncol. 2005;23
104. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J Clin Oncol. 2003;21:2237–2246. [PubMed]
105. Kris MG, Natale RB, Herbst RS, Lynch TJ, Jr., Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA. 2003;290:2149–2158. [PubMed]
106. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial--INTACT 1. J Clin Oncol. 2004;22:777–784. [PubMed]
107. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial--INTACT 2. J Clin Oncol. 2004;22:785–794. [PubMed]
108. Blagosklonny MV, Zarzynkiewicz Z. Why Iressa failed: Toward novel use of kinase inhibitors (outlook) Cancer Biol Ther. 2003;2:137–140. [PubMed]
109. Shepherd FA, Pereira J, Ciulenau TE. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCICCTG) Trial. Proc Am Soc Clin Oncol. 2004:7022.
110. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, Brennscheidt U, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC); Presented at the annual meeting of the American Society of Clinical Oncology; 2004.
111. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, et al. Tribute: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncology. 2005:5892–5899. [PubMed]
112. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004:337–345. [PubMed]
113. Gibson TB, Ranganathan A, Grothey A. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer. 2006;6(1):29–31. [PubMed]
114. Moore MJ, Goldstein D, Hamm J. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCICCTG]; Presented at the annual meeting of the American Society of Clinical Oncology; 2005. [PubMed]
PubReader format: click here to try


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem Compound links
  • EST
    Published EST sequences
  • MedGen
    Related information in MedGen
  • Protein
    Published protein sequences
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links